Braidwell LP Sells 350,200 Shares of X4 Pharmaceuticals, Inc. $XFOR

Braidwell LP lowered its position in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 10.7% in the 2nd quarter, Holdings Channel.com reports. The fund owned 2,922,754 shares of the company’s stock after selling 350,200 shares during the period. Braidwell LP’s holdings in X4 Pharmaceuticals were worth $13,649,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Indivisible Partners purchased a new stake in X4 Pharmaceuticals in the 4th quarter worth approximately $40,000. Rhumbline Advisers grew its position in shares of X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares in the last quarter. SummitTX Capital L.P. purchased a new position in shares of X4 Pharmaceuticals during the 1st quarter valued at $46,000. Pettinga Financial Advisors LLC bought a new position in shares of X4 Pharmaceuticals in the second quarter worth $47,000. Finally, Two Sigma Investments LP purchased a new stake in shares of X4 Pharmaceuticals in the third quarter worth $47,000. Institutional investors own 72.03% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on XFOR shares. Leerink Partners began coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 target price for the company. Wells Fargo & Company assumed coverage on X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target on the stock. Finally, Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 25th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

X4 Pharmaceuticals Price Performance

Shares of NASDAQ:XFOR opened at $4.04 on Thursday. The company’s fifty day moving average price is $4.08 and its 200-day moving average price is $4.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 11.02. The firm has a market capitalization of $400.57 million, a price-to-earnings ratio of -3.37 and a beta of 0.39. X4 Pharmaceuticals, Inc. has a one year low of $2.80 and a one year high of $4.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. The company had revenue of $8.81 million during the quarter, compared to the consensus estimate of $2.42 million. On average, equities research analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.71 earnings per share for the current fiscal year.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $4.26, for a total transaction of $36,393.18. Following the sale, the chief financial officer owned 167,750 shares in the company, valued at $714,615. This trade represents a 4.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Adam R. Craig sold 47,436 shares of X4 Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the sale, the chairman directly owned 328,651 shares of the company’s stock, valued at approximately $1,459,210.44. This trade represents a 12.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 80,555 shares of company stock worth $356,126 over the last 90 days. Corporate insiders own 1.13% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.